{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:55:36Z","timestamp":1793426136637,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.annonc.2025.09.018","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:13:28Z","timestamp":1760710408000},"page":"92-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"S.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-9843","authenticated-orcid":false,"given":"R.","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"D.-W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0817-3400","authenticated-orcid":false,"given":"D.R.","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wan-Teck Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-3916","authenticated-orcid":false,"given":"J.J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-0761","authenticated-orcid":false,"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9833-8576","authenticated-orcid":false,"given":"V.","family":"Henschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Higgerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scalori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Smoljanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.09.018_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2025.09.018_bib2","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2025.09.018_bib3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.018_bib5","first-page":"00063","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non\u2013small-cell lung cancer","volume":"PO.17","author":"Gainor","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib6","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.018_bib7","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.1200\/jco.2013.31.15_suppl.8105","article-title":"Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer","volume":"31","author":"Solomon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/tlcr-22-656","article-title":"Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review","volume":"12","author":"Chazan","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.018_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/EDBK_242209","article-title":"What It takes to improve a first-generation inhibitor to a second- or third-generation small molecule","volume":"39","author":"Rodon Ahnert","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annonc.2025.09.018_bib10","first-page":"94","article-title":"Alectinib and brigatinib: new second-generation ALK inhibitors for the treatment of non-small cell lung cancer","volume":"9","author":"Beardslee","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.018_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2025.09.018_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.018_bib14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100612","article-title":"Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib","volume":"7","author":"Dziadziuszko","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2025.09.018_bib16","first-page":"e2","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.3","volume":"43","author":"Owen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib17","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jtho.2021.07.008","article-title":"Blood first assay screening trial (BFAST) in treatment-naive advanced or metastatic NSCLC: initial results of the phase 2 ALK-positive cohort","volume":"16","author":"Dziadziuszko","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.018_bib20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib21","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cllc.2022.07.008","article-title":"Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic ALK-inhibitor-naive ALK+ non-small cell lung cancer: final results from the phase III ALTA-1L study","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2025.09.018_bib23","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced alk-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib24","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/j.annonc.2024.08.1310","article-title":"1253O Phase I\/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours","volume":"35","author":"Drilon","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.018_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8666","article-title":"Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: the phase 3 ALKAZAR study","volume":"43","author":"Popat","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342504788X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342504788X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:59:21Z","timestamp":1777582761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342504788X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S092375342504788X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.018","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}